en · de · es · fr · pt
peptide-index.peptides7501.com › Topic › Sr9009 Background And Receptor Mechanism — Hands-On Walkthrough

Sr9009 Background And Receptor Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2025-12-25 · last reviewed 2026-01-29 · Topic

nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Related pages on this site

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Notes from published material

=== June === 1 June – A bioRxiv preprint reports the first use of base editing to alter the genome of early human embryos. Researchers at Columbia University used the technique to introduce precise single-letter DNA changes without the large chromosomal alterations previously associated with double-strand-break CRISPR gene editing, while noting that the approach remains far from clinical use and raises ethical questions over human germline engineering. 3 June – A report by the United Nations University Institute for Water, Environment and Health estimates that global data centre electricity consumption could reach 945 TWh by 2030, driven partly by growing demand for artificial intelligence, with associated water use rising to 9.3 trillion litres and carbon dioxide emissions to 399 million tonnes. 4 June – Chinese researchers discover the two-state model of liquid water theorizing that water is composed of two distinct and interconvertible local structures at the high and low density phase boundary. 5 June – Researchers at the University of Cambridge and DIOSynVax report the first human clinical trial of a vaccine whose active component was designed entirely by computer simulations. The candidate pan-Sarbecovirus vaccine, pEVAC-PS, uses a machine-learning-designed "super-antigen"; a phase I trial in 39 healthy volunteers finds it safe and able to trigger immune responses to SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses.

Giant orchid, not to be confused with Eulophia ecristata or Barlia robertiana, both of which are also commonly called the giant orchid. Tiger orchid, not to be confused with Rossioglossum grande or Maxillaria species, both are also called tiger orchid. Queen of the orchids, not to be confused with Cattleya species Sugar cane orchid, for its resemblance to a sugarcane plant of the genus Saccharum

Typically, a centrifugal clutch and sprocket are used. The centrifugal clutch expands with increasing speed, engaging a drum. On this drum sits either a fixed sprocket or an exchangeable one. The clutch has three jobs: When the engine runs idle (typically 2500–2700 rpm) the chain does not move. When the clutch is engaged and the chain stops in the wood for another reason, it protects the engine. Most importantly, it protects the operator in case of a kickback. Here, the chain brake stops the drum, and the clutch releases immediately.

Trump said the bridge's opening will be delayed until multiple trade and bridge related grievances were resolved. Trump's announcement was criticised by politicians, business leaders and industry groups. On February 12, 2026, the United States House of Representatives voted to repeal the tariffs that had been imposed on Canadian goods during Donald Trump's administration. The resolution passed by a 219–211 vote, with a small number of Republican lawmakers joining nearly all Democrats in support. The tariffs had originally been enacted under a national emergency declaration in February 2025, and their repeal represented a rare bipartisan rebuke of Trump's trade policy. Following the vote, President Trump reportedly threatened political consequences for Republicans who voted against the measure. While passage in the House reflects congressional concern over the tariffs, actual repeal would still require Senate approval and presidential assent, and was expected to face a potential veto.

Sources: en.wikipedia.org

Background from the literature

=== Campaigning === Heseltine was not one to befriend and gossip with colleagues or backbenchers. He did not regard this as an insurmountable problem, as neither Heath nor Thatcher had been particularly "clubbable" either. From about the mid-1970s, he began a campaign of addressing local associations, sometimes using a helicopter to speak to several in one day. Heseltine had often had a reputation for being very cold and aloof with backbench MPs and party activists (Steven Norris said that after a visit to his constituency in 1983, local activists used a poster of Heseltine as a dartboard). However, in 1986–1990 he was a frequent visitor to local constituency dinners, although he usually attacked Labour rather than the Conservative government, and he used his wealth to afford a chauffeur and a helicopter. Heseltine campaigned in 100 constituencies in the 1987 election, attracting more publicity than many Cabinet ministers, although seldom mentioning Thatcher by name. During this period Heseltine enjoyed excellent relations with the media: among TV journalists he was in regular touch with Elinor Goodman of Channel 4 News (herself a former Haymarket employee), James Mates of ITN (son of his lieutenant Michael Mates) and John Cole, whilst among print journalists he was close to his old friend Anthony Howard (Deputy Editor of the Observer), Peter Jenkins, and especially close to Anthony Bevins of The Independent and the young Alastair Campbell of the Daily Mirror.

=== Functional ingredient === Pea protein is a low-cost functional ingredient in food manufacturing to improve the nutritional value and texture of food products. It can be used to improve the viscosity, emulsification, gelation, stability, or fat-binding properties of food. For example, the capacity of pea protein to form stable foams is a property used to enhance the production of cakes, souffles, whipped toppings, and fudges.

== Analytical methods == Several HPLC-UV methods have been reported for valdecoxib estimation in biological samples like human urine. Valdecoxib has analytical methods for bioequivalence studies, metabolite determination, estimation of formulation, and an HPTLC method for simultaneous estimation in tablet dosage form.

21 July The Bodyhunters, about the disappearance of Royal Marine Alan Addis; on 8 August 1980, Royal Marine went missing in North Arm; the Forensic Search Advisory Group, from the Home Office, was founded in 1988 by forensic archaeologist John Hunter of the University of Birmingham, with Sgt Mick Swindells of Lancashire Constabulary, providing the first evidence by an archaeologist in a British court; Swindells had found 5 yr old Rosie McCann, of Moorheys in Oldham, in only a few hours in March 1996, after she had disappeared on 14 January 1996 - the local police had been, conversely, searching for seven weeks and had not found anything in that time, and with the generous assistance of RAF search teams; the FSAG adopted a much different searching approach to typical police methods, with archaeology, more educated guesses, and applied geophysics; the individual was part of Naval Party 8901, to train locals in civil defence in 1980; Islands Radio; the team took ground-penetrating radar and five local policemen; three years previously detectives from Devon and Cornwall Police conducted an investigation and arrested four people - three of those were Titch Jaffray, Burnerd Peck and Tony Blake; the team were conducting a nine-day search in 1997; 80-90% of murders have disposal in known areas to the murderer; Chris Johnson was a former Royal Marine; the team looked in the cemetery first, with ground-penetrating radar, which could detect up to three metres below the surface, for irregularities; Tim Cotter, from the Royal Navy; the team knew that any disused buildings would be a plausible hiding place, as nothing is often suspected; in a search site, the team found mixed, or disturbed, soil. Narrated by Robin Ellis, made with the Discovery Channel 28 July Miracle Police, including the Audrey Santo case; personnel of the Roman Catholic Diocese of Worcester; the investigator Joe Nickell; Peter Gumpel of the Congregation for the Causes of Saints; evolutionary psychologist Robin Dunbar; John Polkinghorne of the University of Cambridge; Karen Armstrong, who wrote A History of God; the Lourdes Medical Bureau; Luigi Bommarito, Archbishop from 1988 to 2002 of the Roman Catholic Archdiocese of Catania. Narrated by Piers Gibbon, directed by Alexander Marengo, made by Ideal World with the Discovery Channel 4 August Dawn of the Death Ray, about the laser and its invention in July 1960; physicist Arthur Schawlow, inventor of the laser; testing of lasers took place at Kirtland Air Force Base, New Mexico, where an aircraft was first brought down with a laser in November 1973; a laser-equipped Boeing KC-135 was operated from 1973, by the 4900th Flight Test Group, led by Col John Otten, taking off in January 1975; fighter aircraft would launch air to air missiles, with insufficient fuel, at the aircraft, and the laser would attempt to shoot the missile down; after three years, on 26 May 1983, the laser shot down its first air to air Sidewinder missile; adverse atmospheric conditions often made an airborne laser ineffective; the White Sands Missile Range in New Mexico, and Leik Myrabo of the USAF Advanced Concepts Division; the 1991 Gulf War allowed much advanced technology to be fully evaluated - and Patriot missiles had mostly missed Iraqi Scud missiles; the Directed Energy Directorate of the Air Force Research Laboratory, and its Starfire Optical Range, and physicist Robert Fugate; John V. Breakwell; the USAF ordered seven airborne attack lasers, for delivery by 2008; Major-General Don Lamberson. Narrated by Michael Bywater, directed by Chris Durlacher, produced by David Dugan, made by Windfall Films 11 August Thin Air, about climbers on Mount Everest; in the 1996, eight participants on an Everest expedition died in one day; above 17,000 ft climbers experience weight loss and sleep loss; Peter Hackett (mountaineer); Ed Viesturs from Seattle; David Breashears, who made the documentary; when he was making a film in May 1996, eight climbers died in the 1996 Mount Everest disaster; climbers fly by helicopter to 9,000 ft, then climb to base camp at 17,600 ft; pulmonologist Brownie Schoene of the University of Washington School of Medicine in Seattle; psychologist Gail Rosenbaum; chronic mountain sickness and the portable hyperbaric bag, which is pumped to 2 PSI; the Khumbu Glacier and Khumbu Icefall; Guy Cotter of Adventure Consultants; the 'death zone' is above 26,000 ft; the Lhotse western face; the team reach the South Col, known as Camp VI; the Hillary Step; pulse oximetry and brain MRI scans are taken in Seattle. Broadcast on PBS as Everest - the death zone, when narrated by Jodie Foster. British edition narrated by Piers Gibbon, directed by David Breashears, made by Nova 18 August The Ten Plagues of Egypt, about the Plagues of Egypt in the Book of Exodus; Avi Weiss, who researched the Book of Exodus; doctor John S. Marr looked at the Ipuwer Papyrus, and worked with Curtis Malloy; marine biologist JoAnn Burkholder of North Carolina State University, and how Pfiesteria piscicida could be the first plague; Richard Wassersug of Dalhousie University in Canada, and a plague of frogs; entomologist Richard Brown of Mississippi State University in Starkville, Mississippi; public health entomologist Andrew Spielman of Harvard T.H. Chan School of Public Health; Roger Breeze of Plum Island Animal Disease Center; the final plague was likely caused by Stachybotrys chartarum, which made mycotoxin. Narrated by Jenni Murray, produced by Peter Spry-Leverton, directed by Bill Eagles, made by UFA GmbH and Café Productions, with The Learning Channel

== Further reading == Aird, William C. "Blood Endothelial Cells" in Endothelial Cells In Health and Disease. Boca Raton: Taylor & Francis, 2005. Milosevic, V., Edelmann, R.J., Fosse, J.H., Östman, A., Akslen, L.A. (2022). Molecular Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-030-98950-7_3 Stem Cells, Therapeutic Applications by Mariusz Z. Ratajczak Advances in Experimental Medicine and Biology

Sources: en.wikipedia.org

Reference notes

Product is cooled faster – the smooth round shape of the small crystals ensures maximum surface area contact with the product and as a result, faster heat transfer. Better product protection – the smooth, round crystals do not damage product, unlike other forms of sharp, jagged ice (flake, block, shell, etc.). Even cooling – unlike other irregular shaped ice which mostly conducts heat through the air, the round shape of the slurry crystals enables them to flow freely around the entire product, filling all air pockets to uniformly maintain direct contact and the desired low temperature.

== Research == Paul Kaesberg's research had major impacts on the fields of biochemistry and virology. Some of his most influential research involved bacteriophage morphology, mosaic viruses, and X-ray scattering.

== Regulation == IGFBP-3 levels in human serum are, like IGF-1, dependent on growth hormone (GH); for example, serum IGFBP-3 is increased in acromegaly and low in GH-deficient children. However, IGFBP-3 gene expression in human liver is GH-independent. Because it is stabilized in human serum by forming complexes with IGF-1 and ALS, which are both GH-dependent, serum IGFBP-3 also appears regulated by GH. Its production by some non-hepatic tissues may also be directly GH-regulated. Immunoassays for serum IGFBP-3 are often used as part of the diagnosis of childhood GH-deficiency. The most widely studied IGFBP3 polymorphism, at nucleotide-202 in the promoter region, is significantly associated with circulating IGFBP-3 levels, although the mechanism is unclear. In some studies circulating IGFBP-3 also appears to be nutritionally regulated, although this may not be seen at the mRNA level. IGFBP-3 has been identified in human lymph, nipple aspirate, milk, amniotic fluid, follicular fluid, seminal plasma, urine, peritoneal dialysate, synovial fluid, tear fluid, and cerebrospinal fluid, in addition to serum. Many factors increase IGFBP-3 production by cells, including transforming growth factor-β (TGFβ), tumor necrosis factor-α, vitamin D, retinoic acid, IGF-1, and stimuli such as chemotherapy that activate the tumor suppressor p53. Estrogen inhibits IGFBP-3 production, and its tissue levels are lower in estrogen receptor (ER)-positive breast cancers than in ER-negative cancers.

Histology image: 07903loa – Histology Learning System at Boston University - "Eye: fovea, RPE" Histology image: 08103loa – Histology Learning System at Boston University - "Integument: pigmented skin" UMass Amherst Libraries (2016-04-29). 7. Pigment Transfer in Skin Cells. Retrieved 2026-05-20 – via YouTube.

all persons who were members of the Southern Sudan Legislative Assembly; and all South Sudanese who were members of the National Assembly of Sudan, by virtue of their membership in that Assembly. Members of the Council of Ministers who are not members of the National Legislative Assembly must participate in its deliberations but do not have the right to vote. Persons who wish to become members of the National Legislative Assembly must fulfill the eligibility requirements set down by the Constitution for membership of the National Legislature.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network